Skip to main content

Advertisement

SpringerLink
Log in

Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation

  • Case Report
  • Published:
Prostate Cancer and Prostatic Diseases Submit manuscript

Abstract

We report a 71-year male with castration-resistant metastatic prostate cancer who was treated with weekly docetaxel for 12 weeks and developed significant eye irritation and dryness during treatment. Subsequently, the patient presented with a lower eyelid mass, which on excision was demonstrated to be a chalazion. Docetaxel induced Meibomian duct inflammation and blockage is the likely cause of this presentation in a patient with no history of eyelid masses in the past.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL et al. A multicentre phase II study of docetaxel 75 mg m−2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer. Br J Cancer 1996; 74: 650–656.

    Article  CAS  Google Scholar 

  2. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–2103.

    Article  CAS  Google Scholar 

  3. Mavroudis D, Kourousis C, Androulakis N, Kalbakis K, Agelaki S, Kakolyris S et al. Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial. Am J Clin Oncol 2000; 23: 341–344.

    Article  CAS  Google Scholar 

  4. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512.

    Article  CAS  Google Scholar 

  5. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886–2894.

    Article  CAS  Google Scholar 

  6. Ferraresi V, Milella M, Vaccaro A, D'Ottavio AM, Papaldo P, Nistico C et al. Toxicity and activity of docetaxel in anthracycline-pretreated breast cancer patients: a phase II study. Am J Clin Oncol 2000; 23: 132–139.

    Article  CAS  Google Scholar 

  7. Esmaeli B, Valero V, Ahmadi MA, Booser D . Canalicular stenosis secondary to docetaxel (taxotere): a newly recognized side effect. Ophthalmology 2001; 108: 994–995.

    Article  CAS  Google Scholar 

  8. Perry HD, Serniuk RA . Conservative treatment of chalazia. Ophthalmology 1980; 87: 218–221.

    Article  CAS  Google Scholar 

  9. Esmaeli B, Ahmadi MA, Rivera E, Valero V, Hutto T, Jackson DM et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120: 1180–1182.

    Article  CAS  Google Scholar 

  10. Esmaeli B, Hortobagyi GN, Esteva FJ, Booser D, Ahmadi MA, Rivera E et al. Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer. Ophthalmology 2002; 109: 1188–1191.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, School of Medicine and Biochemical Sciences, State University of New York at Buffalo, Buffalo, NY, USA

    S Gupta

  2. Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA

    C G Silliman & D L Trump

Authors
  1. S Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C G Silliman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D L Trump
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D L Trump.

Additional information

Conflict of interest

No potential conflicts of interest to disclose.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gupta, S., Silliman, C. & Trump, D. Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation. Prostate Cancer Prostatic Dis 10, 396–397 (2007). https://doi.org/10.1038/sj.pcan.4500939

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500939

  • Springer Nature Limited

Keywords

This article is cited by

Search

Navigation